Quick Answer
BioAge Labs, Inc. reported Diluted EPS of $2.24 per share (loss) for fiscal year 2025.
BioAge Labs, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$2.24 | +66.2% |
| 2024 | -$6.63 | +82.6% |
| 2023 | -$38.17 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.56 | +91.6% | +6.7% |
| June 30, 2025 | -$0.60 | +92.4% | -66.7% |
| March 31, 2025 | -$0.36 | +95.4% | +94.6% |
| September 30, 2024 | -$6.70 | +23.3% | +15.6% |
| June 30, 2024 | -$7.94 | — | -2.3% |
| March 31, 2024 | -$7.76 | — | +11.2% |
| September 30, 2023 | -$8.74 | — | — |
- BioAge Labs, Inc. showed an increase of +66.2% in Diluted EPS compared to the prior fiscal year.
- Over the 2023–2025 period, BioAge Labs, Inc.’s diluted eps has grown by 94.1% (from $38.17 per share (loss) to $2.24 per share (loss)).
- The most recent figure is from BioAge Labs, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 24, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: